U.S. Serial No. 09/599,213

Claims 14 and 15 have been amended and are as follows:

13 ~~14.~~ (Amended) The method of claim 1 wherein the pharmaceutically acceptable salt is a methanesulfonate salt.

C2

14 ~~15.~~ (Amended) The method of claim 1 wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 90 wt.% of (S,S) reboxetine, and less than about 10 wt.% of (R,R) reboxetine, based on the total weight of the (S,S) and (R,R) reboxetine present.

Claims 32-38 have been canceled, without prejudice.

New claims 63-76 have been added and are as follows:

17 19 ~~63.~~ The method of claim 39 wherein said composition is administered in an amount of about 0.5 to about 8 mg/day.

20 ~~64.~~ The method of claim 19 ~~63~~ wherein said composition is administered in an amount of about 0.5 to about 5 mg/day.

21 ~~65.~~ The method of claim 20 ~~64~~ wherein said composition is administered in an amount of about 0.5 to about 2.5 mg/day.

C3

22 ~~66.~~ The method of claim 21 ~~65~~ wherein said composition is administered in an amount of about 0.5 to about 0.9 mg/day.

23 ~~67.~~ The method of claim 22 ~~66~~ wherein said composition is administered in an amount of about 0.5 to about 0.8 mg/day.

24 ~~68.~~ The method of claim 23 ~~67~~ wherein said composition is administered in an amount of about 0.5 to about 0.75 mg/day.

25 ~~69.~~ The method of claim 17 ~~39~~ wherein said composition is administered orally, topically, parenterally, transdermally, rectally, or vaginally.

26 ~~70.~~ The method of claim 25 ~~69~~ wherein said composition is orally administered, and further comprising a pharmaceutically acceptable carrier selected from the group consisting of a binder, diluent, lubricant, disintegrating agent, effervescing agent, dyestuff, sweetener, wetting agent, and mixtures thereof.

C

40

[redacted]

27 ~~71.~~ The method of claim ~~70~~ 26 wherein the oral administration is by a sachet, capsule, tablet, or aerosol spray.

28 ~~72.~~ The method of claim ~~69~~ 25 wherein said composition is parenterally administered subcutaneously, intravenously, or intramuscularly.

29 ~~73.~~ The method of claim ~~39~~ 17 wherein the pharmaceutically acceptable salt is a methanesulfonate salt.

C3 Cont.

30 ~~74.~~ The method of claim ~~39~~ 17 wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 90 wt. % of (S,S) reboxetine, and less than about 10 wt. % of (R,R) reboxetine, based on the total weight of the (S,S) and (R,R) reboxetine present.

31 ~~75.~~ The method of claim ~~74~~ 30 wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 97 wt. % of (S,S) reboxetine and less than about 3 wt. % of (R,R) reboxetine, based on the total weight of the (S,S) and (R,R) reboxetine present.

32 ~~76.~~ The method of claim ~~75~~ 31 wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 99 wt. % of (S,S) reboxetine and less than about 1 wt. % of (R,R) reboxetine, based on the total weight of the (S,S) and (R,R) reboxetine present.

41

C

[redacted]